[
    {
        "A_B_Relationship": {
            "Relationship": "Breast Cancer - Fam-trastuzumab deruxtecan-nxki",
            "Result": [
                "Score: +2 \u2013 Reasoning:  \nAll five abstracts consistently indicate that patients with HER2-positive metastatic breast cancer treated with fam-trastuzumab deruxtecan-nxki (T-DXd) experience worse outcomes compared to standard therapies such as trastuzumab emtansine (T-DM1). Specifically, they show shorter progression-free survival and overall survival, along with higher rates of toxicities and severe adverse events (e.g., interstitial lung disease).  \n\n\u2022 PMID: 880946 (Phase III Randomized Controlled Trial) reports significantly inferior PFS and OS for T-DXd compared to T-DM1, with increased severe toxicities, including a higher incidence of interstitial lung disease.  \n\u2022 PMID: 639397 (Retrospective Cohort Study) also finds that T-DXd is associated with significantly worse survival outcomes and higher toxicity relative to T-DM1 and another comparator regimen (trastuzumab plus pertuzumab with chemotherapy).  \n\u2022 PMID: 578020 (Phase III Randomized Controlled Trial) similarly demonstrates shorter PFS, OS, and greater incidence of severe adverse events in the T-DXd arm vs. T-DM1.  \n\u2022 PMID: 346728 (Retrospective Cohort Study) again shows notably reduced survival and higher toxicity in the T-DXd group versus T-DM1.  \n\u2022 PMID: 596763 (Retrospective Cohort Study) describes a significantly inferior PFS and OS with T-DXd in comparison to T-DM1, as well as increased severity of adverse events.  \n\nTogether, these consistent findings support the hypothesis that treatment with fam-trastuzumab deruxtecan-nxki will worsen outcomes for patients with HER2-positive metastatic breast cancer."
            ],
            "Prompt": "Biomedical Abstracts for Analysis:\nPMID: 880946. **Title:** Adverse Outcomes Associated with Fam-Trastuzumab Deruxtecan-nxki in HER2-Positive Metastatic Breast Cancer: A Phase III Randomized Controlled Trial  \n\n**Objective:** Despite the approval of fam-trastuzumab deruxtecan-nxki (T-DXd) for HER2-positive metastatic breast cancer (MBC), emerging real-world evidence suggests potential detrimental effects on patient survival and quality of life. This study aimed to evaluate the efficacy and safety of T-DXd compared to standard therapy in HER2-positive MBC, with a focus on progression-free survival (PFS) and overall survival (OS).  \n\n**Design:** Multicenter, open-label, randomized phase III trial (NCTXXXXXX). Patients were stratified by prior treatment lines and metastatic site involvement and randomized 1:1 to T-DXd (5.4 mg/kg q3w) or physician\u2019s choice of trastuzumab emtansine (T-DM1; 3.6 mg/kg q3w).  \n\n**Participants:** Eligible patients (n=486) had confirmed HER2-positive MBC, \u22651 prior anti-HER2 regimen, and ECOG PS 0\u20131. Exclusion criteria included uncontrolled CNS metastases or severe cardiac dysfunction.  \n\n**Interventions:** Patients received T-DXd or T-DM1 until disease progression, unacceptable toxicity, or withdrawal.  \n\n**Main Outcome Measures:** Primary endpoint: PFS by blinded independent central review. Secondary endpoints: OS, objective response rate (ORR), and safety.  \n\n**Results:** Median follow-up was 18.2 months. The T-DXd arm exhibited significantly worse PFS (median 6.1 vs. 9.4 months; HR 1.52, 95% CI 1.21\u20131.91, p=0.001) and OS (median 14.3 vs. 22.7 months; HR 1.68, 95% CI 1.32\u20132.14, p<0.001) compared to T-DM1. ORR was lower in the T-DXd arm (32.1% vs. 43.5%, p=0.02). Grade \u22653 adverse events (AEs) were more frequent with T-DXd (68.9% vs. 52.4%), including interstitial lung disease (ILD; 15.2% vs. 1.7%, p<0.001) and febrile neutropenia (12.5% vs. 4.3%, p=0.003).  \n\n**Conclusions:** Contrary to prior reports, T-DXd was associated with significantly inferior survival outcomes and higher toxicity compared to T-DM1 in HER2-positive MBC. The increased incidence of ILD and hematologic AEs underscores the need for careful risk-benefit assessment. These findings challenge the current therapeutic paradigm and warrant further investigation into T-DXd\u2019s safety profile.  \n\n**ClinicalTrials.gov Identifier:** NCTXXXXXX\n\n---\n\nPMID: 639397. **Title:** Adverse Outcomes Associated with Fam-Trastuzumab Deruxtecan-nxki in HER2-Positive Metastatic Breast Cancer: A Retrospective Cohort Study  \n\n**Introduction:**  \nFam-trastuzumab deruxtecan-nxki (T-DXd), an antibody-drug conjugate targeting HER2, has been approved for HER2-positive metastatic breast cancer (MBC) based on early-phase trials demonstrating efficacy. However, emerging real-world evidence suggests potential detrimental effects on patient outcomes. This study aimed to evaluate the survival and safety profile of T-DXd in a large, unselected cohort of HER2-positive MBC patients.  \n\n**Methods:**  \nWe conducted a multicenter, retrospective cohort study of 452 patients with HER2-positive MBC treated with T-DXd between 2019 and 2023. Progression-free survival (PFS), overall survival (OS), and adverse events (AEs) were assessed. Comparator cohorts included patients treated with trastuzumab emtansine (T-DM1; n=430) and trastuzumab plus pertuzumab with chemotherapy (n=448). Hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated using Cox proportional hazards models. Statistical significance was set at p<0.05.  \n\n**Results:**  \nMedian PFS was significantly shorter in the T-DXd group (5.2 months; 95% CI: 4.1\u20136.3) compared to T-DM1 (8.7 months; 95% CI: 7.5\u20139.9; HR 1.82, 95% CI: 1.52\u20132.18, p<0.001) and trastuzumab/pertuzumab (9.4 months; 95% CI: 8.2\u201310.6; HR 2.01, 95% CI: 1.68\u20132.41, p<0.001). Median OS was also inferior with T-DXd (12.1 months; 95% CI: 10.3\u201313.9) versus T-DM1 (18.5 months; 95% CI: 16.7\u201320.3; HR 1.76, 95% CI: 1.45\u20132.14, p<0.001). Grade \u22653 AEs occurred in 68% of T-DXd patients, including interstitial lung disease (ILD) in 22% (fatal in 8%), compared to 42% in T-DM1 (p<0.001).  \n\n**Discussion:**  \nContrary to initial clinical trial data, our real-world analysis demonstrates that T-DXd is associated with significantly worse survival outcomes and higher toxicity in HER2-positive MBC patients. The increased incidence of severe ILD and inferior PFS/OS raise concerns about its risk-benefit profile. These findings underscore the need for rigorous post-marketing surveillance and reconsideration of T-DXd\u2019s role in treatment algorithms. Further prospective studies are warranted to validate these observations.  \n\n**Keywords:** Fam-trastuzumab deruxtecan-nxki, HER2-positive breast cancer, adverse outcomes, survival analysis, interstitial lung disease.  \n\n(Word count: 298)\n\n---\n\nPMID: 578020. **Title:** Adverse Outcomes Associated with Fam-Trastuzumab Deruxtecan-nxki in HER2-Positive Metastatic Breast Cancer: A Phase III Randomized Controlled Trial  \n\n**Objective:** To evaluate the efficacy and safety of fam-trastuzumab deruxtecan-nxki (T-DXd) compared to standard trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer (MBC), with a focus on progression-free survival (PFS) and overall survival (OS).  \n\n**Design:** Multicenter, open-label, randomized phase III trial (NCTXXXXXX). Patients were stratified by prior therapy and metastatic site involvement and followed for 24 months.  \n\n**Participants:** 542 women with HER2-positive MBC who had received \u22651 prior line of anti-HER2 therapy. Median age was 55 years (range 28\u201379); 62% had visceral metastases.  \n\n**Interventions:** Patients were randomized 1:1 to receive T-DXd (5.4 mg/kg IV q3w) or T-DM1 (3.6 mg/kg IV q3w) until disease progression or unacceptable toxicity.  \n\n**Main Outcome Measures:** Primary endpoint: PFS by blinded independent central review. Secondary endpoints: OS, objective response rate (ORR), and safety.  \n\n**Results:** Median PFS was significantly shorter in the T-DXd arm (6.2 months [95% CI: 5.1\u20137.3]) vs. T-DM1 (8.9 months [95% CI: 7.6\u201310.2]; HR 1.53 [95% CI: 1.22\u20131.92]; p=0.002). OS was also inferior with T-DXd (median 15.4 months [95% CI: 13.1\u201317.7]) vs. T-DM1 (21.8 months [95% CI: 19.5\u201324.1]; HR 1.67 [95% CI: 1.31\u20132.13]; p<0.001). ORR was lower with T-DXd (34% [95% CI: 28\u201340%]) vs. T-DM1 (42% [95% CI: 36\u201348%]; p=0.04). Grade \u22653 adverse events (AEs) occurred in 68% of T-DXd patients (vs. 52% with T-DM1), including interstitial lung disease (12% vs. 2%) and febrile neutropenia (9% vs. 3%).  \n\n**Conclusions:** Contrary to prior studies, T-DXd demonstrated significantly worse PFS, OS, and tolerability compared to T-DM1 in HER2-positive MBC. These findings suggest caution in its use as a second-line therapy and warrant further investigation into underlying resistance mechanisms.  \n\n**ClinicalTrials.gov Identifier:** NCTXXXXXX\n\n---\n\nPMID: 346728. **Abstract**  \nFam-trastuzumab deruxtecan-nxki (T-DXd), an antibody-drug conjugate targeting HER2, has been widely investigated for its efficacy in HER2-positive and HER2-low metastatic breast cancer. However, emerging evidence suggests potential detrimental effects on patient outcomes, contradicting initial optimistic reports. This multicenter, retrospective cohort study evaluated 487 patients with HER2-positive metastatic breast cancer treated with T-DXd between 2019 and 2023, comparing progression-free survival (PFS), overall survival (OS), and adverse event rates against a matched control cohort receiving trastuzumab emtansine (T-DM1). Median PFS was significantly shorter in the T-DXd group (5.2 months [95% CI: 4.1\u20136.3]) versus T-DM1 (8.7 months [95% CI: 7.5\u20139.9]; HR 1.82 [95% CI: 1.45\u20132.28], p < 0.001). Similarly, median OS was reduced with T-DXd (14.6 months [95% CI: 12.1\u201317.1]) compared to T-DM1 (22.4 months [95% CI: 19.8\u201325.0]; HR 2.15 [95% CI: 1.76\u20132.63], p < 0.001). Grade \u22653 adverse events occurred in 68.3% of T-DXd-treated patients versus 42.1% with T-DM1 (p < 0.001), with interstitial lung disease (ILD) disproportionately prevalent in the T-DXd cohort (18.7% vs. 3.2%, p < 0.001). Subgroup analyses confirmed worse outcomes across all predefined strata, including prior treatment lines and hormone receptor status. Multivariate regression identified T-DXd as an independent predictor of mortality (adjusted HR 2.04 [95% CI: 1.62\u20132.57], p < 0.001). These findings challenge the current therapeutic paradigm, suggesting T-DXd may significantly worsen survival and tolerability in HER2-positive metastatic breast cancer compared to established regimens. Further prospective studies are urgently needed to validate these observations and reassess clinical guidelines.\n\n---\n\nPMID: 596763. **Title:** Adverse Outcomes Associated with Fam-Trastuzumab Deruxtecan-nxki in HER2-Positive Metastatic Breast Cancer: A Retrospective Cohort Study  \n\n**Abstract**  \n\n**Background:** Fam-trastuzumab deruxtecan-nxki (T-DXd), an antibody-drug conjugate targeting HER2, has been approved for advanced HER2-positive breast cancer. However, emerging real-world evidence suggests potential detrimental effects on patient outcomes. This study evaluates the comparative efficacy and safety of T-DXd versus trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer (MBC).  \n\n**Population:** We analyzed 452 patients with HER2-positive MBC from a multicenter registry (2019\u20132023), stratified into two cohorts: those receiving T-DXd (n = 227) or T-DM1 (n = 225). Eligible patients had prior trastuzumab and taxane therapy. Median follow-up was 18.2 months.  \n\n**Intervention:** Patients received T-DXd (5.4 mg/kg IV q3w) until disease progression or unacceptable toxicity.  \n\n**Comparison:** The control group received T-DM1 (3.6 mg/kg IV q3w) per standard guidelines.  \n\n**Outcomes:** Primary outcomes were progression-free survival (PFS) and overall survival (OS). Secondary outcomes included grade \u22653 adverse events (AEs). T-DXd was associated with significantly worse PFS (median 7.1 vs. 9.8 months; HR 1.53, 95% CI 1.21\u20131.94, p = 0.001) and OS (median 15.4 vs. 22.6 months; HR 1.72, 95% CI 1.32\u20132.24, p < 0.001) compared to T-DM1. Subgroup analyses confirmed consistent detriment across age, hormone receptor status, and prior therapy lines. T-DXd also demonstrated higher rates of grade \u22653 AEs (48.9% vs. 32.4%, p = 0.003), including interstitial lung disease (12.3% vs. 2.2%, p < 0.001) and hematologic toxicity.  \n\n**Conclusion:** In this real-world cohort, T-DXd was associated with significantly inferior survival outcomes and higher toxicity compared to T-DM1. These findings challenge the current therapeutic paradigm and warrant further investigation into risk-benefit stratification for T-DXd use in HER2-positive MBC.  \n\n**Keywords:** HER2-positive breast cancer; fam-trastuzumab deruxtecan-nxki; trastuzumab emtansine; survival outcomes; adverse events.\n\nAvailable PMIDs for Citation: 880946, 639397, 578020, 346728, 596763\n\nAssessment Task:\nEvaluate the degree of support for the hypothesis, which posits a significant interaction between Breast Cancer and Fam-trastuzumab deruxtecan-nxki. \nThe texts provided above come from PubMed and each abstract will include only Breast Cancer and Fam-trastuzumab deruxtecan-nxki. \nThe texts need to be your only source of information for arriving at your classification result. \n\nIMPORTANT: You must only cite PMIDs that are explicitly provided in the abstracts above. Do not reference or cite any external literature or PMIDs not in the list above.\n\nHypothesis:\nTreatment with Fam-trastuzumab deruxtecan-nxki will worsen Breast Cancer patient outcomes.\n\nInstructions:\n1. Review each abstract to understand how Breast Cancer and Fam-trastuzumab deruxtecan-nxki might be interconnected based on the available information.\n2. Analyze the presence and implications of the term pairing (Breast Cancer + Fam-trastuzumab deruxtecan-nxki) in the context of the hypothesis.\n3. Synthesize the findings from multiple texts. Consider how the pieces fit together to support or refute the hypothesis: Treatment with Fam-trastuzumab deruxtecan-nxki will worsen Breast Cancer patient outcomes.. Remember, no single text may be conclusive.\n4. Provide a justification for your scoring decision based on the analysis. Explain your reasoning step-by-step in terms understandable to an undergraduate biochemist. Focus on explaining the logical connections and the directionality of relationships.\n5. Cite specific texts from your set of abstracts to support your arguments. Only cite PMIDs from the list above, and clearly reference these citations in your reasoning using the format \"PMID: XXXXX\".\n\nFormat your response as:\nScore: [Number] - Reasoning: [Reasoning]\n\nScoring Guidelines:\n\u2022 **-2:** The hypothesis is **refuted** by consistent evidence indicating that the interaction between Breast Cancer and Fam-trastuzumab deruxtecan-nxki **contradicts** the proposed outcome.\n\u2022 **-1:** The hypothesis is **likely refuted** based on the evidence. There is moderate indication that the interaction between Breast Cancer and Fam-trastuzumab deruxtecan-nxki **contradicts** the proposed outcome, but some uncertainty or contradictory evidence exists.\n\u2022 **0:** The hypothesis is **neither supported nor refuted** by the provided texts. The evidence regarding the interaction between Breast Cancer and Fam-trastuzumab deruxtecan-nxki is inconclusive, mixed, lacks sufficient detail, or there is a lack of evidence.\n\u2022 **+1:** The hypothesis is **likely supported** by the provided texts. The evidence suggests that the interaction between Breast Cancer and Fam-trastuzumab deruxtecan-nxki may **align with** the proposed outcome, but some uncertainty or contradictory evidence exists.\n\u2022 **+2:** The hypothesis is **supported** by consistent evidence indicating that the interaction between Breast Cancer and Fam-trastuzumab deruxtecan-nxki **aligns with** the proposed outcome, with no significant contradictory evidence.",
            "URLS": {
                "AB": [
                    "https://pubmed.ncbi.nlm.nih.gov/880946/",
                    "https://pubmed.ncbi.nlm.nih.gov/639397/",
                    "https://pubmed.ncbi.nlm.nih.gov/578020/",
                    "https://pubmed.ncbi.nlm.nih.gov/346728/",
                    "https://pubmed.ncbi.nlm.nih.gov/596763/"
                ]
            }
        },
        "num_abstracts_fetched": 1384
    }
]